MGTA Profile
Magenta Therapeutics Inc (MGTA) is a biotechnology company focused on developing novel therapies for patients with autoimmune diseases, blood cancers, and genetic diseases. The company's proprietary platform, which uses stem cell science to create medicines, is designed to improve outcomes for patients by harnessing the power of bone marrow transplantation.
Magenta's lead program is MGTA-145, a CD117-targeted antibody-drug conjugate that is being developed as a conditioning agent for bone marrow transplantation. The company is also developing a portfolio of selective immune-resetting agents, including MGTA-117, which is being evaluated in clinical trials for the treatment of autoimmune diseases and blood cancers.
In addition to its internal pipeline, Magenta has formed collaborations with companies including Beam Therapeutics, Heidelberg Pharma, and AVROBIO to explore the potential of its platform technology in developing gene therapies and immuno-oncology treatments.
Magenta was founded in 2015 and is headquartered in Cambridge, Massachusetts.
|
